ATE360004T1 - Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften - Google Patents

Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften

Info

Publication number
ATE360004T1
ATE360004T1 AT02779772T AT02779772T ATE360004T1 AT E360004 T1 ATE360004 T1 AT E360004T1 AT 02779772 T AT02779772 T AT 02779772T AT 02779772 T AT02779772 T AT 02779772T AT E360004 T1 ATE360004 T1 AT E360004T1
Authority
AT
Austria
Prior art keywords
sub
sup
alkyl
heteroaryl
halogen
Prior art date
Application number
AT02779772T
Other languages
English (en)
Inventor
Michela Bettati
Mark Stuart Chambers
Alexander Charles Humphries
Philip Irbm Jones
Richard Thomas Lewis
Robert James Maxey
Helen Jane Szekeres
Martin Richard Teall
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE360004T1 publication Critical patent/ATE360004T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02779772T 2001-11-28 2002-11-27 Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften ATE360004T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0128499.1A GB0128499D0 (en) 2001-11-28 2001-11-28 Therapeutic agents

Publications (1)

Publication Number Publication Date
ATE360004T1 true ATE360004T1 (de) 2007-05-15

Family

ID=9926615

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02779772T ATE360004T1 (de) 2001-11-28 2002-11-27 Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften

Country Status (10)

Country Link
US (1) US20060040940A1 (de)
EP (1) EP1451161B1 (de)
JP (1) JP2005518369A (de)
AT (1) ATE360004T1 (de)
AU (1) AU2002343110B2 (de)
CA (1) CA2468893A1 (de)
DE (1) DE60219672T2 (de)
ES (1) ES2284941T3 (de)
GB (1) GB0128499D0 (de)
WO (1) WO2003048132A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100457756C (zh) * 2003-07-25 2009-02-04 神经能质公司 咪唑-嘧啶类及三唑-嘧啶类:苯并二氮平受体配体
EP1880998A1 (de) * 2003-07-25 2008-01-23 Neurogen Corporation Imidazo-Pyrimide und Triazolo-Pyrimide: Benzodiazepin-Rezeptorliganden
PL1648899T3 (pl) * 2003-07-25 2007-06-29 Neurogen Corp Imidazo-pirymidyny i triazolo-pirymidyny: ligandy benzodiazepinowego receptora
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
EP1863818B1 (de) 2005-03-23 2010-03-10 F.Hoffmann-La Roche Ag Acetylenylpyrazolopyrimidinderivate als mglur2-antagonsten
CN101273040B (zh) 2005-09-27 2011-11-09 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的*二唑基吡唑并嘧啶类化合物
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
AR064491A1 (es) 2006-12-22 2009-04-08 Astex Therapeutics Ltd Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr.
MX2009006704A (es) 2006-12-22 2009-06-30 Astex Therapeutics Ltd Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
EA201000615A1 (ru) 2007-10-17 2010-12-30 Новартис Аг Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
US20110112135A1 (en) * 2007-12-21 2011-05-12 Singhaus Jr Robert Ray Imidazo [1,2-A] Pyridine Compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8222246B2 (en) * 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
KR20190041548A (ko) 2013-03-15 2019-04-22 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
EA201591426A1 (ru) 2013-03-15 2016-02-29 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
GB201321732D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321736D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
BR112015032160B1 (pt) 2014-02-07 2021-11-30 Global Blood Therapeutics, Inc Ansolvato cristalino de composto, composição e composição farmacêutica
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
CN111587114A (zh) * 2017-11-14 2020-08-25 儿童医学中心公司 用于调节人免疫应答的咪唑并嘧啶的用途
JP7304855B2 (ja) 2017-11-14 2023-07-07 ザ チルドレンズ メディカル センター コーポレーション 新規イミダゾピリミジン化合物およびそれらの使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9503601D0 (en) * 1995-02-23 1995-04-12 Merck Sharp & Dohme Method of treatment and method of manufacture of medicament
BR9710729A (pt) * 1996-07-25 1999-08-17 Merck Sharp & Dohme Composto composi-Æo farmac-utica utiliza-Æo de um composto e processo para o tratamento e/ou a preven-Æo da ansiedade e de convuls{es para a triagem de compostos ansioliticos nÆo-sedativos e para a prepara-Æo de um composto
AU724076B2 (en) * 1996-07-25 2000-09-14 Merck Sharp & Dohme Limited Substituted triazolo pyridazine derivatives as inverse agonists of the GABAAalpha5 receptor subtype
AU732455C (en) * 1997-05-08 2002-09-05 Merck Sharp & Dohme Limited Substituted 1,2,4-triazolo{3,4-a}phthalazine derivatives as gaba alpha 5 ligands
YU46500A (sh) * 1998-02-25 2002-11-15 Merck Charp & Dohme Limited Substituisani 1,2,4-triazolo /3,4-a/piridazin
GB9824897D0 (en) * 1998-11-12 1999-01-06 Merck Sharp & Dohme Therapeutic compounds
GB9927687D0 (en) * 1999-11-23 2000-01-19 Merck Sharp & Dohme Therapeutic agents
US6355638B1 (en) * 1999-11-25 2002-03-12 Merck Sharp & Dohme Ltd. Pyrazolo[1,5-d][1,2,4] triazines for enhancing cognition
CA2410037C (en) * 2000-05-24 2009-11-03 Merck Sharp & Dohme Limited 3-phenyl-imidazo-pyrimidine derivatives as ligands for gaba receptors
GB0017518D0 (en) * 2000-07-17 2000-08-30 Merck Sharp & Dohme Therapeutic agents
GB0017543D0 (en) * 2000-07-17 2000-09-06 Merck Sharp & Dohme Therapeutic agents
GB0117277D0 (en) * 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
EP1343788B1 (de) * 2000-11-10 2005-11-23 MERCK SHARP & DOHME LTD. Imidazotriazin-derivate als liganden für gaba-rezeptoren
TWI248936B (en) * 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
GB0125086D0 (en) * 2001-10-18 2001-12-12 Merck Sharp & Dohme Novel compounds
GB0225501D0 (en) * 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
US7485640B2 (en) * 2002-11-06 2009-02-03 Merck Sharp & Dohme Limited Imidazopyrazinones as GABA-A receptor anxiolytics
US6967255B2 (en) * 2004-02-06 2005-11-22 Industrial Technology Research Institute Phenanthrene compounds

Also Published As

Publication number Publication date
GB0128499D0 (en) 2002-01-23
AU2002343110B2 (en) 2008-10-30
WO2003048132A1 (en) 2003-06-12
DE60219672D1 (de) 2007-05-31
AU2002343110A1 (en) 2003-06-17
DE60219672T2 (de) 2007-12-27
EP1451161B1 (de) 2007-04-18
US20060040940A1 (en) 2006-02-23
JP2005518369A (ja) 2005-06-23
ES2284941T3 (es) 2007-11-16
CA2468893A1 (en) 2003-06-12
EP1451161A1 (de) 2004-09-01

Similar Documents

Publication Publication Date Title
ATE360004T1 (de) Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften
AR037682A1 (es) Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
DK1261602T3 (da) Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
BR0314392A (pt) Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
BR0212760A (pt) Compostos quìmicos
AR035935A1 (es) El empleo de un antagonista del receptor de nk-1 y una composicion farmaceutica que lo comprende
DE69120100T2 (de) Annelierte Thiophen-Derivate, ihre Herstellung und Verwendung
DE602004012758D1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
EA200000700A3 (ru) НОВЫЕ β- КАРБОЛИНОВЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ
ATE530187T1 (de) Pharmazeutische zubereitungen mit nk1-rezeptor- antagonisten und natriumkanalblockern
ATE530182T1 (de) Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen
TR200000727T2 (tr) 5HT geri alım inhibitörü ve h5-HT1B antagonistinin bir bileşimi.
WO2005040345A3 (en) 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
BRPI0506848A (pt) composto,uso do mesmo, formulação farmacêutica e produto farmacêutico
HRP20090147T3 (en) Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer
ATE277897T1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
AR059490A1 (es) Cmpuestos antivirales heterociclicos
AR037611A1 (es) Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
MX2012008147A (es) Derivados de pirrazolopiridina.
EA200301171A1 (ru) Новые соединения трициклических дигидрохинолинов, способ их получения и фармацевтические композиции, содержащие их
NO20041704L (no) Substituerte alkylaminopyridazinonderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som inneholder disse
DE60210981D1 (de) Heteroarylheteroalkylamin derivate und deren verwendung als inhibitoren der stickoxidsynthase
ATE370140T1 (de) Kondensierte bicyclische pyrimidinderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties